Form 4: Aardvark Therapeutics Director Susan E. Graf Granted 30,508 Stock Options

Aardvark Therapeutics, Inc. Director Susan E. Graf was granted 30,508 stock options with an exercise price of $11.29, vesting in full on June 11, 2026.

Summary

• Susan E. Graf, a Director of Aardvark Therapeutics, Inc. (AARD), was granted 30,508 stock options.
• The stock options have an exercise price of $11.29 per share.
• The grant date for these options was June 11, 2025.
• The options are scheduled to vest in full on June 11, 2026, contingent upon Ms. Graf's continuous service through that date.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Ms. Graf directly beneficially owns 30,508 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, and represents a standard compensation practice. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a substantial window for potential value realization if the stock price appreciates.

Risks

• The value of the stock options is directly dependent on the future market performance of Aardvark Therapeutics' common stock; if the stock price does not exceed the exercise price of $11.29, the options may expire worthless.
• The vesting of the options is conditional on the director's continuous service, meaning the options could be forfeited if service ceases before the full vesting date of June 11, 2026.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future operational or financial performance.

Industry Context

The grant of stock options to a director is a standard equity compensation practice within the biotechnology and pharmaceutical industries, designed to align the long-term interests of company leadership with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a common and widely accepted practice across publicly traded companies, including those in the biotechnology sector, to incentivize long-term commitment and performance.
• The exercise price of $11.29 is typically set at the fair market value of Aardvark Therapeutics' common stock on the grant date, which is standard for incentive stock options.
• A 10-year expiration period (until June 11, 2035) is typical for employee and director stock options, providing ample time for the stock price to appreciate.
• The one-year cliff vesting schedule (full vesting on June 11, 2026) is a common vesting approach, although multi-year graded vesting is also prevalent in the industry.

Related Party Transactions

• The grant of stock options to Susan E. Graf, a Director of Aardvark Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value, though it also represents potential future dilution if options are exercised.
• Employees: This specific filing does not indicate any direct impact on general employees.

Next Steps

• The granted options will vest in full on June 11, 2026, provided the director maintains continuous service.
• After vesting and before the expiration date of June 11, 2035, the director may choose to exercise these options to acquire common stock, assuming the market price is favorable.

Key Dates

Keywords

Aardvark Therapeutics, AARD, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Susan E Graf